BioNexus Gene Lab Corp. Appoints Dr. Muthu Meyyappan as CCO of Fidelion Diagnostics to Lead VitaGuard™ MRD Commercialization

BioNexus Gene Lab Corp. appointed Dr. Muthu Meyyappan as CCO of Fidelion Diagnostics to lead global commercialization of the VitaGuard™ MRD precision oncology platform. The appointment aims to strengthen market presence in the minimal residual disease testing segment.